The estimated Net Worth of Michael James Morrissey is at least $4.49 Million dollars as of 29 March 2021. Mr Morrissey owns over 20,000 units of Incyte stock worth over $2,869,385 and over the last 5 years he sold INCY stock worth over $1,621,600.
Mr has made over 1 trades of the Incyte stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of INCY stock worth $1,621,600 on 29 March 2021.
The largest trade he's ever made was selling 20,000 units of Incyte stock on 29 March 2021 worth over $1,621,600. On average, Mr trades about 1,111 units every 0 days since 2020. As of 29 March 2021 he still owns at least 45,452 units of Incyte stock.
You can see the complete history of Mr Morrissey stock trades at the bottom of the page.
Michael James Morrissey is the Exec. VP & Head of Global Technical Operations at Incyte.
Mr Morrissey is 57, he's been the Exec. VP & Head of Global Technical Operations of Incyte since . There are 15 older and 11 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.
Michael's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19803.
Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B..., and Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
Incyte executives and other stock owners filed with the SEC include: